Based on our hypothesis, the selective advantage for the MEFV mutation carrier can partly rely on the expected mechanism that β2MG can be released into the cytoplasm by the trigger due to infection and that following pyrin inflammasome activation may have a pivotal role in the control of infection. Here, MEFV is linked to infection.